Ligand Pharmaceuticals, Inc. (LGND)
280.18
-6.11
(-2.13%)
USD |
NASDAQ |
Aug 24, 16:00
281.89
+1.71
(+0.61%)
Pre-Market: 07:59
Ligand Pharmaceuticals Profit Margin (Quarterly) : 76.16% for June 30, 2026
Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 76.16% |
| March 31, 2026 | -25.80% |
| December 31, 2025 | 75.06% |
| September 30, 2025 | |
| June 30, 2025 | 10.18% |
| March 31, 2025 | -93.64% |
| December 31, 2024 | -72.62% |
| September 30, 2024 | -13.84% |
| June 30, 2024 | -125.0% |
| March 31, 2024 | |
| December 31, 2023 | 64.72% |
| September 30, 2023 | -31.26% |
| June 30, 2023 | 8.69% |
| March 31, 2023 | 99.17% |
| December 31, 2022 | -28.85% |
| September 30, 2022 | 16.29% |
| June 30, 2022 | 25.13% |
| March 31, 2022 | -35.41% |
| December 31, 2021 | -5.66% |
| September 30, 2021 | 21.17% |
| June 30, 2021 | 36.29% |
| March 31, 2021 | 32.83% |
| December 31, 2020 | 8.23% |
| September 30, 2020 | -16.01% |
| June 30, 2020 | 53.32% |
| Date | Value |
|---|---|
| March 31, 2020 | -72.77% |
| December 31, 2019 | -27.27% |
| September 30, 2019 | -61.48% |
| June 30, 2019 | -57.71% |
| March 31, 2019 | |
| December 31, 2018 | -71.29% |
| September 30, 2018 | |
| June 30, 2018 | 81.25% |
| March 31, 2018 | 80.63% |
| December 31, 2017 | -13.89% |
| September 30, 2017 | 25.25% |
| June 30, 2017 | 21.64% |
| March 31, 2017 | 17.35% |
| December 31, 2016 | -8.19% |
| September 30, 2016 | 4.86% |
| June 30, 2016 | -31.61% |
| March 31, 2016 | 19.82% |
| December 31, 2015 | 29.92% |
| September 30, 2015 | |
| June 30, 2015 | |
| March 31, 2015 | -0.61% |
| December 31, 2014 | 29.28% |
| September 30, 2014 | 5.19% |
| June 30, 2014 | 12.14% |
| March 31, 2014 | 13.14% |
Profit Margin Definition
Profit Margin is calculated using Net Income/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into profit. An analyst looking at profit margin might look for a higher profit margin relative to other comparable companies as well as a profit margin that is growing.
Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Profit Margin (Quarterly) Benchmarks
| Johnson & Johnson | 21.86% |
| Eli Lilly & Co. | 30.88% |
| Merck & Co., Inc. | -8.06% |
| Zevra Therapeutics, Inc. | 21.16% |
| Liquidia Corp. | 43.52% |
Profit Margin (Quarterly) Related Metrics
| Return on Equity | 20.71% |
| Return on Assets | 12.80% |
| Return on Invested Capital | 13.60% |
| Gross Profit Margin (Quarterly) | 82.24% |
| Operating Margin (Quarterly) | 13.49% |
| Return on Net Operating Assets | 32.65% |